Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ107 in lymphopenic patients with newly diagnosed glioblastoma after chemoradiotherapy
CTR20202070Phase 2Active
- Sponsor
- I-Mab
- Start
- Feb 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efineptakin alfa in glioblastoma (GBM), sponsored by I-Mab. Started Feb 2021; status: active.
02
Drugs
efineptakin alfa
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20202070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202070.